HISOAR(SZ:002099) Tong Hua Shun Cai Bao·2025-04-28 10:48Financial Performance - The company reported a basic earnings per share of -0.2100 yuan for 2024, an improvement of 19.23% compared to -0.2600 yuan in 2023 [1] - The total revenue decreased to 19.38 billion yuan in 2024, down 10.77% from 21.72 billion yuan in 2023 [1] - The net profit for 2024 was -3.3 billion yuan, showing a 21.43% improvement from -4.2 billion yuan in 2023 [1] - The return on equity was -6.19% in 2024, an improvement from -7.18% in 2023 [1] Shareholder Information - The top ten unrestricted shareholders collectively hold 80,509.77 million shares, accounting for 49.83% of the circulating shares, with a decrease of 1,685.38 million shares compared to the previous period [1] - Zhejiang Donggang Industrial Co., Ltd. remains the largest shareholder with 52,398.26 million shares, representing 32.43% of the total share capital, unchanged from the previous period [2] - The employee stock ownership plan of Zhejiang Haixiang Pharmaceutical Co., Ltd. saw a reduction of 197.72 million shares, now holding 2,952.37 million shares [2] Dividend Policy - The company has decided not to distribute dividends or increase capital [1]